Genmab A (GMAB) Net Cash Flow Growth (1y) (2019 - 2026)
Genmab A (GMAB) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 53.46% |
| 10 | Genmab A | 1.88 Bn | 356.56 Mn | 831.00 Mn | -179.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -179.22% |
| Sep 30, 2025 | 129.08% |
| Jun 30, 2025 | 94.45% |
| Mar 31, 2025 | 403.95% |
| Dec 31, 2024 | -634.67% |
| Sep 30, 2020 | -100.00% |
| Dec 31, 2019 | -100.00% |